Who
Daphne Karydas
Director
Company insider
Files Form 4 as: Director, Mineralys Therapeutics; Director, COMPASS Pathways; Director, LogicBio Therapeutics; Chief Financial Officer, Syndax Pharmaceuticals.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $1.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 10 Dec 2020
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K3,000 at $28.58 | filing |
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 15 Sep 2026filed 17 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K3,000 at $28.58 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,000 at $25.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 17 Jun 2026filed 17 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,000 at $25.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,000 at $25.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,000 at $12.02 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,000 at $25.00 | filing |
News
Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas Sells 3,000 Sharesthemarketsdaily.com · 18 Sep 2026
1 headline in the last 90 days name Daphne Karydas; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.